



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034, Phone:040-23547532,
Email : investors@natcopharma.co.in CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2021

(All amounts in ₹ millions except for share data)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	5,605	3,772	3,552	13,480	17,208	20,521
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	910	698	801	2,518	5,089	5,796
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	910	698	801	2,518	5,089	5,796
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) attributable to owners of the parent	804	651	627	2,205	3,879	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	1,082	583	668	2,483	3,896	4,496
6	Paid-up equity share capital of ₹ 2 each	365	365	364	365	364	365
7	Other equity (Revaluation reserve ₹ Nil)						40,851
8	Earnings Per Share (in Rupees) per ₹ 2/-share (non-annualised)						
	1. Basic	4.41	3.57	3.44	12.09	21.30	24.20
	2. Diluted	4.40	3.57	3.43	12.08	21.25	24.16

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under.

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	5,295	3,304	3,309	12,537	13,420	16,535
2	Profit before tax	797	523	707	2,230	3,188	3,922
3	Net profit for the period/ year	716	536	547	2,004	2,523	3,095
4	Total comprehensive income	1,020	513	551	2,372	2,593	3,228

2 "The above is an extract of the detailed format of Financial Results for the Quarter and Nine months ended 31 December, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine Months ended 31 December, 2021 Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."

3 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14 February, 2022.

4 "The Board of Directors at their meeting held on 14 February, 2022 have recommended an interim dividend of ₹ 2.00 per equity share of ₹ 2 each."

Place: Hyderabad

Date: 14 February, 2022

for and on behalf of Board of Directors

NATCO Pharma Limited

Sd/- V.C. Nannapaneni, Chairman & Managing Director



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034. Phone:040-23547532,
Email : investors@natcopharma.co.in CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2021

(All amounts in ₹ millions except for share data)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	5,605	3,772	3,552	13,480	17,208	20,521
2	Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	910	698	801	2,518	5,089	5,796
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	910	698	801	2,518	5,089	5,796
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) attributable to owners of the parent	804	651	627	2,205	3,879	4,409
5	Total Comprehensive Income for the period attributable to owners of the parent	1,082	583	668	2,483	3,896	4,496
6	Paid-up equity share capital of ₹ 2 each	365	365	364	365	364	365
7	Other equity (Revaluation reserve ₹ Nil)						40,851
8	Earnings Per Share (in Rupees) per ₹ 2/-share (non-annualised)						
	1. Basic	4.41	3.57	3.44	12.09	21.30	24.20
	2. Diluted	4.40	3.57	3.43	12.08	21.25	24.16

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under.

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	5,295	3,304	3,309	12,537	13,420	16,535
2	Profit before tax	797	523	707	2,230	3,188	3,922
3	Net profit for the period/ year	716	536	547	2,004	2,523	3,095
4	Total comprehensive income	1,020	513	551	2,372	2,593	3,228

2 "The above is an extract of the detailed format of Financial Results for the Quarter and Nine months ended 31 December, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine Months ended 31 December, 2021 Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."

3 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14 February, 2022.

4 "The Board of Directors at their meeting held on 14 February, 2022 have recommended an interim dividend of ₹ 2.00 per equity share of ₹ 2 each."

Place: Hyderabad

Date: 14 February, 2022

Nava Telangana 15/02/2022

for and on behalf of Board of Directors
NATCO Pharma Limited

Sd/- V.C. Nannapaneni, Chairman & Managing Director

Financial Express 15/02/2022



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad - 500 034.
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

NOTICE

DECLARATION OF 3rd INTERIM DIVIDEND AND RECORD DATE

The Company hereby informs that the Board of Directors at their meeting held on 14th February 2022 declared an Interim Dividend of Rs. 2.00 (100%) per equity Share of Rs.2/- each of the Company. The Interim Dividend will be paid to the shareholders of the Company whose name appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on 25th February, 2022, being the Record Date fixed for the purpose. The payment of said Interim dividend will be start from 4th March, 2022.

For NATCO Pharma Limited

Sd/- M. Adinarayana

Company Secretary & Vice President
(Legal & Corporate Affairs)

Place : Hyderabad
Date : 14-02-2022

hs)

r

20
ed

Hyderabad Telangana, North: 30 wide road, 1000

Nava Telangana 15/02/2022

Email ID : sales@munara.in TOLL FREE : 1800 572 6047



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad - 500 034.
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

NOTICE

DECLARATION OF 3rd INTERIM DIVIDEND AND RECORD DATE

The Company hereby informs that the Board of Directors at their meeting held on 14th February 2022 declared an Interim Dividend of Rs. 2.00 (100%) per equity Share of Rs.2/- each of the Company. The Interim Dividend will be paid to the shareholders of the Company whose name appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on 25th February, 2022, being the Record Date fixed for the purpose. The payment of said Interim dividend will be start from 4th March, 2022.

For NATCO Pharma Limited

Sd/- M. Adinarayana

Company Secretary & Vice President
(Legal & Corporate Affairs)

Place : Hyderabad
Date : 14-02-2022